ACRS
Aclaris Therapeutics Inc.
$1.93
+$0.02(+1.05%)
36
Overall
--
Value
36
Tech
--
Quality
Market Cap
$199.33M
Volume
1.14M
52W Range
$1.05 - $5.17
Target Price
$7.86
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | -- | -- | $1.7M | $6.2M | $4.2M | $6.5M | $6.8M | $29.8M | $31.2M | $18.7M | ||
| Total Revenue | -- | -- | $1.7M | $6.2M | $4.2M | $6.5M | $6.8M | $29.8M | $31.2M | $18.7M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | $-1.2M | $-4.3M | $4.1M | $5.1M | $4.7M | $12.0M | $3.4M | $15.5M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | -- | -- | $476.0K | $1.8M | $172.0K | $1.3M | $2.0M | $17.8M | $27.8M | $3.3M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-20.7M | $-48.6M | $-72.9M | $86.6M | $92.7M | $49.9M | $67.4M | $102.9M | $130.8M | $55.8M | ||
| Research & Development | $15.3M | $33.5M | $39.8M | $60.8M | $64.9M | $29.3M | $43.8M | $77.8M | $98.4M | $33.6M | ||
| Research Expense | $15.3M | $33.5M | $39.8M | $60.8M | $64.9M | $29.3M | $43.8M | $77.8M | $98.4M | $33.6M | ||
| Selling, General & Administrative | $5.3M | $15.1M | $33.1M | $25.8M | $27.8M | $20.5M | $23.6M | $25.1M | $32.4M | $22.2M | ||
| Selling & Marketing Expenses | -- | -- | $13.8M | $170.0K | $4.7M | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $5.3M | $15.1M | $19.3M | $25.6M | $27.8M | $20.5M | $23.6M | $25.1M | $32.4M | $22.2M | ||
| Promotion & Advertising | -- | -- | -- | -- | $4.1M | -- | -- | -- | -- | -- | ||
| Salaries & Wages | $-891.0K | $-6.1M | $-14.4M | $-16.6M | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-90.0K | $-120.0K | $-370.0K | $-1.2M | $1.5M | $1.1M | $800.0K | $700.0K | $800.0K | $700.0K | ||
| Depreciation & Amortization | $-90.0K | $-120.0K | $-370.0K | $-1.2M | $1.5M | $1.1M | $4.7M | $700.0K | -- | -- | ||
| Amortization | -- | -- | $-31.0K | $-75.0K | $518.0K | $7.2M | $7.0M | $75.0K | $75.0K | -- | ||
| Other Operating Expenses | $-20.7M | $-48.6M | $-72.9M | $-138.7M | $1.0M | $1.0M | $1.0M | $1.0M | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-20.7M | $-48.6M | $-72.4M | $-84.8M | $-111.1M | $-50.9M | $-89.7M | $-89.9M | $-97.4M | $-141.9M | ||
| EBITDA | $-20.5M | $-48.0M | $-70.0M | $-80.2M | $-107.0M | $-47.2M | $-64.5M | $-84.4M | $-88.0M | $-131.3M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | $87.0K | $5.0K | -- | $4.0M | -- | -- | ||
| Intinc | -- | -- | -- | -- | -- | -- | -- | -- | $8.5M | $8.0M | ||
| Net Non-Operating Interest Income/Expense | -- | -- | -- | -- | $-87.0K | $-5.0K | -- | $-4.0M | $8.5M | $8.0M | ||
| Gain on Sale of Securities | $89.0K | $152.0K | $678.0K | $487.0K | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $-104.0K | $-488.0K | $-2.1M | $-2.7M | $6.5M | $2.8M | $25.5M | $-1.8M | $-26.9M | $586.0K | ||
| Other Special Charges | $104.0K | $488.0K | $2.1M | $2.7M | $-2.5M | $-424.0K | $-1.1M | $2.9M | $8.5M | $1.9M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | $2.7M | $100.0K | -- | -- | -- | -- | ||
| Special Income Charges | -- | -- | -- | -- | $-18.5M | $-100.0K | -- | -- | $-3.1M | $-2.7M | ||
| Impairment of Capital Assets | -- | -- | -- | -- | $18.5M | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-20.6M | $-48.1M | $-70.4M | $-82.1M | $-113.5M | $-48.5M | $-65.4M | $-85.2M | $-88.8M | $-132.1M | ||
| Pre-Tax Income | $-20.6M | $-48.1M | $-70.4M | $-82.1M | $-113.5M | $-51.3M | $-90.9M | $-86.9M | $-88.8M | $-132.1M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | $-1.8M | -- | -- | $-182.0K | -- | -- | $-367.0K | -- | ||
| NET INCOME | ||||||||||||
| Net Income | $-20.6M | $-48.1M | $-68.5M | $-82.7M | $-161.4M | $-51.0M | $-90.9M | $-86.9M | $-88.5M | $-132.1M | ||
| Net Income (Continuing Operations) | $-20.6M | $-48.1M | $-68.5M | $-82.7M | $-161.4M | $-51.0M | $-90.9M | $-86.9M | $-88.5M | $-132.1M | ||
| Net Income (Discontinued Operations) | $-20.6M | $-48.1M | $-68.5M | $-82.7M | $-161.4M | $-51.0M | $-90.9M | $-86.9M | $-88.5M | $-132.1M | ||
| Net Income (Common Stockholders) | $-23.1M | $-48.1M | $-68.5M | $-82.7M | $-113.5M | $-51.0M | $-90.9M | $-86.9M | $-88.5M | $-132.1M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-20.7M | $-48.6M | $-74.1M | $82.3M | $96.8M | $55.0M | $72.1M | $114.9M | $134.2M | $71.2M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $6.1M | $21.4M | $28.1M | $32.9M | $41.3M | $42.5M | $56.7M | $65.2M | $69.8M | $77.3M | ||
| Average Shares Outstanding (Diluted) | $5.4M | $21.4M | $28.1M | $20.5M | $41.3M | -- | $56.7M | $65.2M | $69.8M | $77.3M | ||
| Shares Outstanding | $20.2M | $26.1M | $30.9M | $41.3M | $41.5M | $51.8M | $108.3M | $66.7M | $70.9M | $107.9M | ||
| Basic EPS | -- | -- | -- | -- | $-3.9 | $-1.2 | $-1.6 | $-1.33 | $-1.27 | $-1.71 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-3.9 | $-1.2 | $-1.6 | $-1.33 | $-1.27 | $-1.71 | ||
| Diluted EPS | $-3.79 | $-2.25 | $-2.44 | $-4.03 | $-3.9 | $-1.2 | $-1.6 | $-1.33 | $-1.27 | $-1.71 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-1.6 | $-1.33 | $-1.27 | $-1.71 | ||
| OTHER METRICS | ||||||||||||
| Accretion On Preferred Stock | $2.6M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Basic Discontinuous Operations | -- | -- | -- | -- | $-1.16 | -- | -- | -- | -- | -- | ||
| Development Expense | -- | -- | -- | -- | -- | -- | -- | $4.0M | -- | -- | ||
| Diluted Discontinuous Operations | -- | -- | -- | $-1.54 | -- | -- | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | -- | -- | $200.0K | -- | -- | -- | -- | -- | ||
| Gains Loss On Disposal Of Discontinued Operations | -- | -- | -- | $-552.0K | $1.4M | $139.0K | -- | -- | -- | -- | ||
| Net Income Discontinuous Operations | -- | -- | -- | $-552.0K | $-63.1M | $-285.0K | -- | -- | -- | -- | ||
| Other Gain Loss From Disposition Of Discontinued Operations | -- | -- | -- | -- | $13.9M | $424.0K | -- | -- | -- | -- | ||
| Other Gand A | $5.3M | $15.1M | $19.3M | $25.6M | $27.8M | $20.5M | $23.6M | $25.1M | $32.4M | $22.2M | ||
| Other Impairment Of Capital Assets | $-289.0K | $-216.0K | -- | -- | $4.1M | -- | -- | -- | $6.6M | -- | ||
| Otherunder Preferred Stock Dividend | $2.6M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Preferred Stock Dividends | $2.6M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $5.3M | $15.1M | $19.3M | $25.6M | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | -- | -- | $13.8M | $170.0K | -- | -- | -- | -- | -- | -- | ||
| Write Down | -- | -- | -- | -- | -- | $5.1M | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | $2.7M | $100.0K | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ACRS | $1.93 | +1.0% | 1.14M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Aclaris Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW